Allergan
Allergan, officially known as Allergan plc, is a prominent global pharmaceutical company headquartered in the United States. Founded in 1948, Allergan has established itself as a leader in the biopharmaceutical industry, focusing on areas such as medical aesthetics, eye care, and neuroscience. The company is renowned for its innovative products, including the widely recognised Botox, which has transformed both cosmetic and therapeutic treatments. With major operational regions spanning North America, Europe, and Asia, Allergan has achieved significant milestones, including its acquisition by AbbVie in 2020, further solidifying its market position. The company’s commitment to research and development has led to a diverse portfolio of unique offerings, making it a key player in enhancing patient outcomes and quality of life.
DitchCarbon Score
How does Allergan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan's reported carbon emissions
In 2017, Allergan reported total greenhouse gas emissions of approximately 88,190,000 kg CO2e for Scope 1, 46,800,000 kg CO2e for Scope 2 (market-based), and 250,000,000 kg CO2e for Scope 3 emissions. This data is cascaded from its parent company, AbbVie Inc., reflecting Allergan's status as a current subsidiary. The emissions for 2016 were slightly lower, with Scope 1 emissions at about 85,464,000 kg CO2e, Scope 2 emissions (market-based) at 50,279,000 kg CO2e, and consistent Scope 3 emissions of 250,000,000 kg CO2e. In 2015, the figures were similar, with Scope 1 emissions at approximately 85,405,000 kg CO2e and Scope 2 emissions (market-based) at 62,403,000 kg CO2e. Allergan has not disclosed specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction targets suggests a need for further development in their sustainability strategy. The company’s emissions data is inherited from Allergan plc, with performance metrics sourced from the same entity, indicating a unified approach to emissions reporting within the corporate family. Overall, Allergan's emissions profile highlights significant Scope 3 emissions, which typically represent the largest share of total emissions for companies in the pharmaceutical sector, underscoring the importance of comprehensive strategies to address these impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
